{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:08:21Z","timestamp":1784610501763,"version":"3.55.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T00:00:00Z","timestamp":1600128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T00:00:00Z","timestamp":1600128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["NCI CA180888, CA180819, CA180820, CA180821, CA180868, CA180863"],"award-info":[{"award-number":["NCI CA180888, CA180819, CA180820, CA180821, CA180868, CA180863"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009634","name":"Susan G. Komen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Berlex"},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s00520-020-05748-8","type":"journal-article","created":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T23:14:10Z","timestamp":1600125250000},"page":"2509-2517","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307)"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7925-2785","authenticated-orcid":false,"given":"Darya A.","family":"Kizub","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieling","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark M.","family":"Schubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander H. G.","family":"Paterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Clemons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth C.","family":"Dees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James N.","family":"Ingle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla I.","family":"Falkson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Barlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel N.","family":"Hortobagyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie R.","family":"Gralow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,15]]},"reference":[{"issue":"10001","key":"5748_CR1","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(15)60908-4","volume":"386","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2015","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG) (2015) Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 386(10001):1353\u20131361","journal-title":"Lancet."},{"issue":"18","key":"5748_CR2","first-page":"2062","volume":"35","author":"S Dhesy-Thind","year":"2017","unstructured":"Dhesy-Thind S, Fletcher GG, Blanchette PS, Clemons MJ, Dillmon MS, Frank ES, Gandhi S, Gupta R, Mates M, Moy B, Vandenberg T, van Poznak CH (2017) Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline. Clin Oncol 35(18):2062\u20132081","journal-title":"Clin Oncol"},{"issue":"8","key":"5748_CR3","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","volume":"30","author":"F Cardoso","year":"2019","unstructured":"Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, Zackrisson S (2019) Senkus E; ESMO Guidelines Committee. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 30(8):1194\u20131220","journal-title":"Ann Oncol"},{"issue":"3","key":"5748_CR4","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/annonc\/mdv617","volume":"27","author":"P Hadji","year":"2016","unstructured":"Hadji P, Coleman RE, Wilson C, Powles TJ, Cl\u00e9zardin P, Aapro M, Costa L, Body JJ, Markopoulos C, Santini D, Diel I, Di Leo A, Cameron D, Dodwell D, Smith I, Gnant M, Gray R, Harbeck N, Thurlimann B, Untch M, Cortes J, Martin M, Albert US, Conte PF, Ejlertsen B, Bergh J, Kaufmann M, Holen I (2016) Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. Ann Oncol 27(3):379\u2013390","journal-title":"Ann Oncol"},{"issue":"Suppl 2","key":"5748_CR5","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1053\/j.seminoncol.2010.10.007","volume":"37","author":"T Guise","year":"2010","unstructured":"Guise T (2010) Examining the metastatic niche: targeting the microenvironment. Semin Oncol 37(Suppl 2):S2\u2013S14","journal-title":"Semin Oncol"},{"issue":"20 Pt 2","key":"5748_CR6","doi-asserted-by":"crossref","first-page":"6222 s","DOI":"10.1158\/1078-0432.CCR-06-0843","volume":"12","author":"AJ Roelofs","year":"2006","unstructured":"Roelofs AJ, Thompson K, Gordon S, Rogers MJ (2006) Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 12(20 Pt 2):6222 s\u20136230 s","journal-title":"Clin Cancer Res"},{"issue":"24","key":"5748_CR7","doi-asserted-by":"crossref","first-page":"10022","DOI":"10.1073\/pnas.0702254104","volume":"104","author":"RT Guo","year":"2007","unstructured":"Guo RT, Cao R, Liang PH, Ko TP, Chang TH, Hudock MP, Jeng WY, Chen CKM, Zhang Y, Song Y, Kuo CJ, Yin F, Oldfield E, Wang AHJ (2007) Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases. Proc Natl Acad Sci U S A 104(24):10022\u201310027","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"5748_CR8","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1359\/jbmr.2000.15.11.2211","volume":"15","author":"O Fromigue","year":"2000","unstructured":"Fromigue O, Lagneaux L, Body JJ (2000) Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 15(11):2211\u20132221","journal-title":"J Bone Miner Res"},{"issue":"1","key":"5748_CR9","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.bone.2010.07.016","volume":"48","author":"P Clezardin","year":"2011","unstructured":"Clezardin P (2011) Bisphosphonates antitumor activity: an unrevealed side of a multifaceted drug class. Bone. 48(1):71\u201379","journal-title":"Bone."},{"issue":"9","key":"5748_CR10","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","volume":"61","author":"RE Marx","year":"2003","unstructured":"Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61(9):1115\u20131117","journal-title":"J Oral Maxillofac Surg"},{"issue":"10","key":"5748_CR11","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","volume":"72","author":"SL Ruggiero","year":"2014","unstructured":"Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O'Ryan F, American Association of Oral and Maxillofacial Surgeons (2014) American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg 72(10):1938\u20131956","journal-title":"J Oral Maxillofac Surg"},{"issue":"1","key":"5748_CR12","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1634\/theoncologist.2010-0183","volume":"16","author":"RA Miksad","year":"2011","unstructured":"Miksad RA, Lai KC, Dodson TB, Woo SB, Treister NS, Akinyemi O, Bihrle M, Maytal G, August M, Gazelle GS, Swan JS (2011) Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw. Oncologist. 16(1):121\u2013132","journal-title":"Oncologist."},{"key":"5748_CR13","doi-asserted-by":"crossref","first-page":"427273","DOI":"10.1155\/2014\/427273","volume":"2014","author":"PI Melea","year":"2014","unstructured":"Melea PI, Melakopoulos I, Kastritis E et al (2014) Conservative treatment of bisphosphonate-related osteonecrosis of the jaw in multiple myeloma patients. Int J Dent 2014:427273","journal-title":"Int J Dent"},{"issue":"8","key":"5748_CR14","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/j.joms.2011.08.033","volume":"70","author":"FS O\u2019Ryan","year":"2012","unstructured":"O\u2019Ryan FS, Lo JC (2012) Bisphosphonate-related osteonecrosis of the jaw in patients with oral bisphosphonate exposure: clinical course and outcomes. J Oral Maxillofac Surg 70(8):1844\u20131853","journal-title":"J Oral Maxillofac Surg"},{"issue":"3","key":"5748_CR15","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jfma.2012.04.010","volume":"113","author":"LW Lee","year":"2014","unstructured":"Lee LW, Hsiao SH, Chen LK (2014) Clinical treatment outcomes for 40 patients with bisphosphonates-related osteonecrosis of the jaws. J Formos Med Assoc 113(3):166\u2013172","journal-title":"J Formos Med Assoc"},{"issue":"9","key":"5748_CR16","first-page":"3917","volume":"33","author":"AT Assaf","year":"2013","unstructured":"Assaf AT, Smeets R, Riecke B, Weise E, Gr\u00f6be A, Blessmann M, Steiner T, Wikner J, Friedrich RE, Heiland M, Hoelzle F, Gerhards F (2013) Incidence of bisphosphonate-related osteonecrosis of the jaw in consideration of primary diseases and concomitant therapies. Anticancer Res 33(9):3917\u20133924","journal-title":"Anticancer Res"},{"issue":"4","key":"5748_CR17","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.coms.2015.06.001","volume":"27","author":"T Aghaloo","year":"2015","unstructured":"Aghaloo T, Hazboun R, Tetradis S (2015) Pathophysiology of osteonecrosis of the jaws. Oral Maxillofac Surg Clin North Am 27(4):489\u2013496","journal-title":"Oral Maxillofac Surg Clin North Am"},{"issue":"3","key":"5748_CR18","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.oooo.2013.05.005","volume":"116","author":"SE Pichardo","year":"2013","unstructured":"Pichardo SE, van Merkesteyn JP (2013) Bisphosphonate related osteonecrosis of the jaws: spontaneous or dental origin? Oral Surg Oral Med Oral Pathol Oral Radiol 116(3):287\u2013292","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"8","key":"5748_CR19","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1007\/s00784-016-1718-2","volume":"20","author":"JW Kim","year":"2016","unstructured":"Kim JW, Landayan ME, Lee JY et al (2016) Role of microcracks in the pathogenesis of bisphosphonate-related osteonecrosis of the jaw. Clin Oral Investig 20(8):2251\u20132258","journal-title":"Clin Oral Investig"},{"issue":"8","key":"5748_CR20","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1634\/theoncologist.2008-0091","volume":"13","author":"CL Estilo","year":"2008","unstructured":"Estilo CL, Van Poznak CH, Wiliams T et al (2008) Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy. Oncologist. 13(8):911\u2013920","journal-title":"Oncologist."},{"issue":"4","key":"5748_CR21","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.clbc.2011.02.001","volume":"11","author":"N Ngamphaiboon","year":"2011","unstructured":"Ngamphaiboon N, Frustino JL, Kossoff EB, Sullivan MA, O\u2019Connor TL (2011) 1. Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with\/without bevacizumab. Clin Breast Cancer 11(4):252\u2013257","journal-title":"Clin Breast Cancer"},{"issue":"6","key":"5748_CR22","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.oooo.2012.08.444","volume":"114","author":"PP Sedghizadeh","year":"2012","unstructured":"Sedghizadeh PP, Yooseph S, Fadrosh DW, Zeigler-Allen L, Thiagarajan M, Salek H, Farahnik F, Williamson SJ (2012) Metagenomic investigation of microbes and viruses in patients with jaw osteonecrosis associated with bisphosphonate therapy. Oral Surg Oral Med Oral Pathol Oral Radiol 114(6):764\u2013770","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"5748_CR23","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s12967-015-0568-z","volume":"13","author":"S Kalyan","year":"2015","unstructured":"Kalyan S, Wang J, Quabius ES, Huck J, Wiltfang J, Baines JF, Kabelitz D (2015) Systemic immunity shapes the oral microbiome and susceptibility to bisphosphonate-associated osteonecrosis of the jaw. J Transl Med 13:212","journal-title":"J Transl Med"},{"issue":"11","key":"5748_CR24","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1177\/0022034511420430","volume":"90","author":"H Mawardi","year":"2011","unstructured":"Mawardi H, Giro G, Kajiya M, Ohta K, Almazrooa S, Alshwaimi E, Woo SB, Nishimura I, Kawai T (2011) A role of oral bacteria in bisphosphonate-induced osteonecrosis of the jaw. J Dent Res 90(11):1339\u20131345","journal-title":"J Dent Res"},{"issue":"2","key":"5748_CR25","volume":"10","author":"JH Kim","year":"2015","unstructured":"Kim JH, Ko YJ, Kim JY, Oh Y, Hwang J, Han S, Kim S, Lee JH, Han DH (2015) Genetic investigation of bisphosphonate-related osteonecrosis of jaw (BRONJ) via whole exome sequencing and bioinformatics. PLoS One 10(2):e0118084","journal-title":"PLoS One"},{"key":"5748_CR26","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.bone.2018.05.001","volume":"112","author":"S Kuroshima","year":"2018","unstructured":"Kuroshima S, Sasaki M, Nakajima K, Tamaki S, Hayano H, Sawase T (2018) Prevalence of bisphosphonate-related osteonecrosis of the jaw-like lesions is increased in a chemotherapeutic dose-dependent manner in mice. Bone. 112:177\u2013186","journal-title":"Bone."},{"issue":"9","key":"5748_CR27","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.oraloncology.2007.11.012","volume":"44","author":"T Boonyapakorn","year":"2008","unstructured":"Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G (2008) Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 44(9):857\u2013869","journal-title":"Oral Oncol"},{"issue":"2","key":"5748_CR28","first-page":"209","volume":"91","author":"AE Lungu","year":"2018","unstructured":"Lungu AE, Lazar MA, Tonea A, Rotaru H, Roman RC, Badea ME (2018) Observational study of the bisphosphonate-related osteonecrosis of jaws. Clujul Med 91(2):209\u2013215","journal-title":"Clujul Med"},{"issue":"3","key":"5748_CR29","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.otorri.2014.06.003","volume":"66","author":"A Pelaz","year":"2015","unstructured":"Pelaz A, Junquera L, Gallego L, Garc\u00eda-Consuegra L, Garc\u00eda-Mart\u00ednez L, Cutilli T, Olay S (2015) Epidemiology, pharmacology and clinical characterization of bisphosphonate-related osteonecrosis of the jaw. A retrospective study of 70 cases. Acta Otorrinolaringol Esp 66(3):139\u2013147","journal-title":"Acta Otorrinolaringol Esp"},{"issue":"2","key":"5748_CR30","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/lary.20076","volume":"119","author":"S Saussez","year":"2009","unstructured":"Saussez S, Javadian R, Hupin C, Magremanne M, Chantrain G, Loeb I, Decaestecker C (2009) Bisphosphonate-related osteonecrosis of the jaw and its associated risk factors: a Belgian case series. Laryngoscope. 119(2):323\u2013329","journal-title":"Laryngoscope."},{"issue":"5","key":"5748_CR31","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1524-4741.2011.01119.x","volume":"17","author":"D Quispe","year":"2011","unstructured":"Quispe D, Shi R, Burton G (2011) Osteonecrosis of the jaw in patients with metastatic breast cancer: ethnic and socio-economic aspects. Breast J 17(5):510\u2013513","journal-title":"Breast J"},{"key":"5748_CR32","first-page":"CD012432","volume":"10","author":"NH Beth-Tasdogan","year":"2017","unstructured":"Beth-Tasdogan NH, Mayer B, Hussein H, Zolk O (2017) Interventions for managing medication-related osteonecrosis of the jaw. Cochrane Database Syst Rev 10:CD012432","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"5748_CR33","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.oooo.2019.08.004","volume":"128","author":"JJ Heifetz-Li","year":"2019","unstructured":"Heifetz-Li JJ, Abdelsamie S, Campbell CB, Roth S, Fielding AF, Mulligan JP (2019) Systematic review of the use of pentoxifylline and tocopherol for the treatment of medication-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol 128(5):491\u2013497.e2","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"4","key":"5748_CR34","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.oooo.2015.10.033","volume":"121","author":"JP Bodem","year":"2016","unstructured":"Bodem JP, Schaal C, Kargus S, Saure D, Mertens C, Engel M, Hoffmann J, Freudlsperger C (2016) Surgical management of bisphosphonate-related osteonecrosis of the jaw stages II and III. Oral Surg Oral Med Oral Pathol Oral Radiol 121(4):367\u2013372","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"21","key":"5748_CR35","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1200\/JCO.2012.46.4792","volume":"31","author":"EJ Rathbone","year":"2013","unstructured":"Rathbone EJ, Brown JE, Marshall HC, Collinson M, Liversedge V, Murden GA, Cameron D, Bell R, Spensley S, Agrawal R, Jyothirmayi R, Chakraborti P, Yuille F, Coleman RE (2013) Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01\/04). J Clin Oncol 31(21):2685\u20132691","journal-title":"J Clin Oncol"},{"key":"5748_CR36","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jbo.2018.09.008","volume":"13","author":"RE Coleman","year":"2018","unstructured":"Coleman RE, Collinson M, Gregory W, Marshall H, Bell R, Dodwell D, Keane M, Gil M, Barrett-Lee P, Ritchie D, Bowman A, Liversedge V, De Boer RH, Passos-Coelho JL, O\u2019Reilly S, Bertelli G, Joffe J, Brown JE, Wilson C, Tercero JC, Jean-Mairet J, Gomis R, Cameron D (2018) Benefits and risks of adjuvant treatment with zoledronic acid in stage II\/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01\/04). J Bone Oncol 13:123\u2013135","journal-title":"J Bone Oncol"},{"issue":"7","key":"5748_CR37","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1470-2045(11)70122-X","volume":"12","author":"M Gnant","year":"2011","unstructured":"Gnant M, Mlineritsch B, Stoeger H (2011) et al; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 12(7):631\u2013641","journal-title":"Lancet Oncol"},{"key":"5748_CR38","doi-asserted-by":"crossref","unstructured":"Gralow JR, Barlow WE, Paterson AHG, et al (2020) Phase III randomized trial of bisphosphonates as adjuvant therapy in breast cancer: S0307. J Natl Cancer Inst 112(7):698\u2013707","DOI":"10.1093\/jnci\/djz215"},{"issue":"3","key":"5748_CR39","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s10549-009-0432-z","volume":"116","author":"D Mauri","year":"2009","unstructured":"Mauri D, Valachis A, Polyzos IP, Polyzos NP, Kamposioras K, Pesce LL (2009) Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a meta-analysis. Breast Cancer Res Treat 116(3):433\u2013439","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"5748_CR40","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/odi.12966","volume":"25","author":"SY Jung","year":"2019","unstructured":"Jung SY, Suh HS, Park JW, Kwon JW (2019) Drug holiday patterns and bisphosphonate-related osteonecrosis of the jaw. Oral Dis 25(2):471\u2013480","journal-title":"Oral Dis"},{"issue":"7","key":"5748_CR41","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/S1470-2045(12)70226-7","volume":"13","author":"AH Paterson","year":"2012","unstructured":"Paterson AH, Anderson SJ, Lembersky BC et al (2012) Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol 13(7):734\u2013742. https:\/\/doi.org\/10.1016\/S1470-2045(12)70226-7","journal-title":"Lancet Oncol"},{"issue":"2","key":"5748_CR42","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1186\/bcr1384","volume":"8","author":"T Powles","year":"2006","unstructured":"Powles T, Paterson A, McCloskey E, Schein P, Scheffler B, Tidy A, Ashley S, Smith I, Ottestad L, Kanis J (2006) Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res 8(2):R13","journal-title":"Breast Cancer Res"},{"issue":"4","key":"5748_CR43","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/odi.12632","volume":"23","author":"P Fung","year":"2017","unstructured":"Fung P, Bedogni G, Bedogni A, Petrie A, Porter S, Campisi G, Bagan J, Fusco V, Saia G, Acham S, Musto P, Petrucci MT, Diz P, Colella G, Mignogna MD, Pentenero M, Arduino P, Lodi G, Maiorana C, Manfredi M, Hallberg P, Wadelius M, Takaoka K, Leung YY, Bonacina R, Schi\u00f8dt M, Lakatos P, Taylor T, de Riu G, Favini G, Rogers SN, Pirmohamed M, Nicoletti P, GENVABO Consortium, Fedele S (2017) Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study. Oral Dis 23(4):477\u2013483","journal-title":"Oral Dis"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05748-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-020-05748-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05748-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T03:03:04Z","timestamp":1631674984000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-020-05748-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,15]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["5748"],"URL":"https:\/\/doi.org\/10.1007\/s00520-020-05748-8","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,15]]},"assertion":[{"value":"5 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Ingle reports grants from U.S. National Cancer Institute, during the conduct of the study. Dr. Falkson reports grants from Seattle Genetics, grants from Pfizer, other from Biotheranostics, other from Agendia, grants from Genentech\/Roche, other from ExactSciences\/OncotypeDx, outside the submitted work. Dr. Barlow reports grants from the National Cancer Institute, during the conduct of the study. Dr. Hortobagyi reports grants and personal fees from Novartis, outside the submitted work. Dr. Gralow reports other from Roche\/Genentech, other from Novartis, other from Radius, other from Astra Zeneca, other from Pfizer, other from Puma, other from Immunomedics, other from Seattle Genetics, other from Sandoz\/Hexal AG, outside the submitted work. All other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. All patients provided written informed consent. The study was approved by the National Cancer Institute Central Institutional Review Board (IRB), as well as by IRBs of participating institutions and monitored by an independent data safety monitoring committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Does not apply","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Does not apply","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}